The importance of testing for mutations in the 3 codons (G12, G13 and Q61) in KRAS commonly mutated in NSCLC was demonstrated by the detection of 13% more KRAS positive patients in this clinical cohort. This evidence concerns the gene KRAS and non-small cell lung carcinoma.